Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2024: Net sales and
earnings below the strong prior-year quarter - Annual forecast confirmed

EQS-Ad-hoc: Drägerwerk AG & Co. KGaA / Key word(s): Preliminary
Results/Forecast
Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2024: Net sales and
earnings below the strong prior-year quarter - Annual forecast confirmed

15-Apr-2024 / 19:14 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation
(EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Ad-hoc notification in accordance with Sec. 17 of the MAR

Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2024: Net sales and
earnings below the strong prior-year quarter - Annual forecast confirmed

Lübeck, April 15, 2024 - In the first quarter, which is traditionally weak
for Dräger, the Company once again achieved a positive operating result of
around EUR 15 million based on preliminary calculations. However, earnings
and net sales declined as expected after the exceptional improvement in the
same quarter of the previous year. In the first quarter of 2023, Dräger had
benefited from catch-up effects as a result of the noticeable improvement in
delivery capability. In addition, a surge in demand for ventilators in China
had led to higher net sales. As expected, both effects were absent in the
first quarter of 2024.

Net sales in the first quarter of 2024 decreased by 2.6 percent (net of
currency effects; nominal: -3.3 percent) to around EUR 736 million (Q1 2023:
EUR 761.1 million). The safety division continued its growth and recorded an
increase of 10.0 percent (net of currency effects; nominal: 9.3 percent) to
around EUR 318 million (Q1 2023: EUR 291.2 million). The medical division
saw a decline of 10.4 percent (net of currency effects; nominal: -11.2
percent) to around EUR 417 million (Q1 2023: EUR 469.9 million), which is
attributable in particular to the two base effects in the prior year. The
Group's gross margin increased to around 45.3 percent (Q1 2023: 45.0
percent). Earnings before interest and taxes (EBIT) amounted to around EUR
15 million (Q1 2023: EUR 29.1 million). The EBIT margin amounted to around
2.0 percent (Q1 2023: 3.8 percent).

Demand for Dräger products and services remained high overall. The
preliminary calculated order intake increased by 1.5 percent (net of
currency effects; nominal: 0.9 percent) to around EUR 811 million and was
therefore above the high prior-year level (Q1 2023: EUR 803.8 million). In
the safety division, order intake rose by 6.1 percent (net of currency
effects; nominal: 5.5 percent) to around EUR 357 million (Q1 2023: EUR 338.4
million). In the medical division, it decreased by 1.9 percent (net of
currency effects; nominal: -2.5 percent) to around EUR 454 million (Q1 2023:
EUR 465.3 million).

Dräger confirms its forecast for the year and continues to expect net sales
growth of 1.0 to 5.0 percent (net of currency effects) and an EBIT margin of
2.5 to 5.5 percent.

The full results for the first three months of the fiscal year will be
published on April 25, 2024.

Drägerwerk AG & Co. KGaA
Moislinger Allee 53-55
23558 Lübeck, Germany
www.draeger.com

Investor Relations:
Thomas Fischler
Tel. +49 451 882-2685
thomas.fischler@draeger.com

Corporate Communications:
Melanie Kamann
Tel. +49 451 882-3998
melanie.kamann@draeger.com

Disclaimer
This ad hoc report contains statements on the future development of Dräger
Group. These forward-looking statements are based on the current
expectations, presumptions, and forecasts of the Executive Board as well as
the information available to date. They were compiled to the best of the
company's knowledge. Dräger does not provide any warranty nor assume any
responsibility for the future developments and results described above.
These are dependent on a number of factors. They entail various risks and
contingencies outside of the company's influence and are based on
assumptions which could prove to be incorrect. Dräger does not assume any
responsibility for updating the forward-looking statements contained in this
report. This does not infringe any legal stipulations on the adjustment of
forecasts. Please go to Investor Relations / Definitions of financial
indicators at www.draeger.com for information on alternative performance
measures used.


End of Inside Information

---------------------------------------------------------------------------

15-Apr-2024 CET/CEST The EQS Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Drägerwerk AG & Co. KGaA
                   Moislinger Allee 53-55
                   23558 Lübeck
                   Germany
   Phone:          +49 (0)451 882-0
   Fax:            +49 (0)451 882-2080
   E-mail:         info@draeger.com
   Internet:       www.draeger.com
   ISIN:           DE0005550602, DE 000 555 063 6, DE 000 555 071 9
   WKN:            555060, 555063 Vorzüge, 555071 Genussschein D
   Indices:        SDAX
   Listed:         Regulated Market in Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Berlin, Stuttgart,
                   Tradegate Exchange
   EQS News ID:    1880883

End of Announcement EQS News Service
---------------------------------------------------------------------------

1880883 15-Apr-2024 CET/CEST